3 Reasons to Buy Grail (GRAL) Hand Over Fist in October
The cancer blood test maker could have a bright future.
Overview
Grail (NASDAQ: GRAL), which was spun off from Illumina (NASDAQ: ILMN) in 2024, develops a blood test for detecting signals from dozens of cancers before any symptoms appear. Its stock endured some wild swings over the past two years, but it now trades near a record high. Let's see why Grail's stock is soaring -- and the three main reasons it's still worth buying today.
Image source: Getty Images.
Grail isn't a speculative, pre-revenue company. The FDA hasn't approved Grail's Galleri blood test yet. Still, it's already sold on a cash-only basis (for $749 to $949) to independent customers, select employers, hospital pilot programs, and telehealth services.
Details
Source
Originally published at www.fool.com.